Bayer Expects Pharma Sales Dip in 2025 Despite Upcoming Launches

Bayer's 2025 Pharmaceutical Outlook

Bayer projects a decline in pharmaceutical sales for 2025, ranging between -2% to +2% growth4
The company expects overall 2025 sales of €45-47 billion, representing -3% to +1% growth9
EBITDA before special items forecast at €9.5-10 billion, a 1-6% decline at constant currencies9
Core earnings per share expected between €4.50-5.00 at constant currencies9

Factors Impacting 2025 Outlook

Loss of exclusivity for top-selling drug Xarelto in most markets during 20242
Negative product mix effect from accelerated Xarelto decline9

Upcoming launches of new drugs expected to partially offset revenue losses:

Potential launch of acoramidis for ATTR-CM in Europe7
Anticipated launch of elinzanetant for menopausal symptoms7
Planned launch of Beyonttra in European markets starting April 20259

Long-Term Strategy

Bayer expects pharmaceutical growth to resume from 2027 onwards4
Margin expansion in the pharmaceutical division anticipated by 20284
Focus on strengthening pipeline in oncology, cardiology, neurology, and immunology5
Targeting over €3.5 billion in additional Crop Science sales from innovation by 20294

Bayer is navigating a challenging period in 2025 due to patent expirations but aims to return to growth in subsequent years through new product launches and pipeline development.